Topics
Glioblastoma | Outcomes | Tumor Treating Fields
Home > Publications > Topics > Glioblastoma > Outcomes > Tumor Treating Fields
*Kanamori M, Tsuzuki S, Shibahara I, Saito K, Shimoda Y, Tanaka K,
Yamaguchi S, Natsumeda M, Matsutani T, Hanihara M, Nakada M,
Kuroda JI, Matsuda M, Yoshimoto K, Yonezawa U, Sonoda Y, Takano K,
Yonezawa H, Otani Y, Nakahara Y, Uchida M, Nonaka M, Mineharu Y,
Kitamura Y, Yamashita S, Yamauchi T, Miyake Y, Deguchi S, Beppu T,
Tamura K, Koizumi S, Hirose Y, Asano K, Hiruta R, Kinoshita M,
Miyake K, Nakayama N, Inoue A, Ono T, Sasaki T, Akiyama Y, Fukami
S, Yoshino A, Kawanishi Y, Asanome T, Yamaguchi T, Takahashi M,
Yamasaki F, Arakawa Y, Narita Y.
Impact
of tumor-treating fields on the survival of Japanese patients with
newly diagnosed glioblastoma: A multicenter, retrospective cohort
study.
Neurooncol Adv. 2024 Nov 28;6(1):vdae176. doi:
10.1093/noajnl/vdae176. PMID:
39659832. Observational study. ˍ
Riegel
DC, Bureau BL, Conlon P, Chavez G, Connelly JM.
Long-term
survival, patterns of progression, and patterns of use for
patients with newly diagnosed glioblastoma treated with or without
Tumor Treating Fields (TTFields) in a real-world setting.
J
Neurooncol. 2025 Mar 31. doi:
10.1007/s11060-025-04946-w. PMID:
40163248. Observational study.
ˍ